Calithera Biosciences Inc (CALA) Given Consensus Rating of “Hold” by Brokerages

Shares of Calithera Biosciences Inc (NASDAQ:CALA) have earned a consensus recommendation of “Hold” from the eight brokerages that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $16.75.

Several research firms recently commented on CALA. Zacks Investment Research cut Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine cut Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. Finally, BidaskClub cut Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 18th.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its stake in Calithera Biosciences by 37.3% during the fourth quarter. BlackRock Inc. now owns 2,886,275 shares of the biotechnology company’s stock worth $24,099,000 after purchasing an additional 784,816 shares during the last quarter. FMR LLC lifted its stake in Calithera Biosciences by 85.8% during the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock worth $40,349,000 after purchasing an additional 1,254,900 shares during the last quarter. State Street Corp lifted its stake in Calithera Biosciences by 5,802.1% during the second quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock worth $19,370,000 after purchasing an additional 1,282,275 shares during the last quarter. Vanguard Group Inc. lifted its stake in Calithera Biosciences by 29.7% during the second quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock worth $17,813,000 after purchasing an additional 274,510 shares during the last quarter. Finally, Ascend Capital LLC lifted its stake in Calithera Biosciences by 5.4% during the fourth quarter. Ascend Capital LLC now owns 693,801 shares of the biotechnology company’s stock worth $5,792,000 after purchasing an additional 35,606 shares during the last quarter. 72.89% of the stock is owned by hedge funds and other institutional investors.

Calithera Biosciences (NASDAQ:CALA) traded up $0.17 during trading on Tuesday, reaching $7.07. The company had a trading volume of 533,191 shares, compared to its average volume of 458,889. Calithera Biosciences has a twelve month low of $6.57 and a twelve month high of $20.05. The stock has a market capitalization of $251.00, a PE ratio of -7.14 and a beta of 2.56.

TRADEMARK VIOLATION NOTICE: “Calithera Biosciences Inc (CALA) Given Consensus Rating of “Hold” by Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/13/calithera-biosciences-inc-cala-given-consensus-rating-of-hold-by-brokerages.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply